Development of high performance Affimer®-based diagnostics to improve health outcomes.
Avacta aims to become the leading provider of innovative, next generation diagnostic solutions, and the first choice for disruptive immunodiagnostic products.
Our diagnostics division is utilising our proprietary Affimer® platform to develop AffiDX® in vitro diagnostic (IVD) tests, starting with the AffiDX® SARS-CoV-2 Antigen Lateral Flow Test.
We have also established commercial relationships with IVD companies worldwide to improve the clinical utility of diagnostic testing solutions, by combining bespoke Affimer® reagents with leading diagnostic platform technologies.
Make an enquiry
Find out more about how Affimer® technology could be the solution to your needs.Read More
Discover why Affimers® reagents are ideal tools for developing diagnostic productsExplore
Find out why Affimer® reagents are the perfect solution to fast-forward your diagnostic development.Explore